Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Imutec reports positive phase I/II results for Virulizin

Sep. 7, 1998

New biologic for breast cancer receives advisory committee approval

Sep. 3, 1998

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Sep. 2, 1998

Medarex receives milestone payment from Merck KGaA

Sep. 2, 1998

Techniclone advancing development of Tumor Necrosis Therapy into phase II

Sep. 2, 1998

Pivotal clinical trial data for rituximab published

Aug. 28, 1998

Imutec receives patent protection for Virulizin in Canada

Aug. 24, 1998

Available from NIH: immunotoxin for the treatment of ovarian cancer and mesotheliomas

Aug. 20, 1998

BLP25 cancer vaccine enters phase I testing in patients with NSCLC

Aug. 19, 1998

Canadian patent covers Jenner's cancer vaccine

Aug. 13, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 15, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld MedTech
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...